Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If […]
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
Zymeworks Announces Participation in Upcoming Investor Conferences
